Sanofi American Depositary Receipt (SNW2)
Summary
SNW2 Chart
Sanofi: How I Leveraged This Undervalued Dividend Aristocrat
Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat. New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%.
Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks
SNY beats on Q2 earnings and sales as Dupixent tops euro 5B in quarterly sales for the first time. The company also raises its 2026 outlook.
Sanofi Q2 Earnings Call Highlights
Sanofi NASDAQ: SNY raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongoing review of its research pipeline and broader growth strategy.
Sanofi American Depositary Receipt (SNW2) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sanofi American Depositary Receipt ever had a stock split?
Sanofi American Depositary Receipt Profile
| Pharmaceuticals Industry | Healthcare Sector | Belén Garijo López CEO | XDUS Exchange | US80105N1054 ISIN |
| FR Country | 76,493 Employees | 4 May 2026 Last Dividend | 30 Sep 2013 Last Split | - IPO Date |
Overview
Sanofi is a global leader in healthcare, deeply engaged in the journey of pushing the boundaries of medicine to improve health outcomes across the world. Founded in 1973 and headquartered in Paris, France, the company has evolved its name from Sanofi-Aventis to Sanofi in May 2011, marking a milestone in its expansive history. With a robust presence in the United States, Europe, and various international markets, Sanofi undertakes the research, development, manufacture, and marketing of therapeutic solutions through a comprehensive portfolio segmented into Pharmaceuticals, Vaccines, and Consumer Healthcare. The company's dedication to innovation is underscored by its collaborations, including a notable one with GlaxoSmithKline for a Covid-19 vaccine and a research venture with Stanford University School of Medicine focused on immunology and inflammation. Furthermore, Sanofi's partnership with Prellis Biologics, Inc., showcases its commitment to exploring new horizons in healthcare solutions.
Products and Services
- Specialty Care Products: Sanofi delivers cutting-edge treatments in various therapeutic areas. This includes human monoclonal antibodies, treatments for multiple sclerosis, neurology, inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders. These products underline Sanofi's commitment to addressing complex health conditions with innovative solutions.
- Diabetes and Cardiovascular Products: The company offers a range of medicines for diabetes care, showcasing its role in battling this global epidemic. Additionally, it provides products for cardiovascular health, emphasizing the importance of managing heart-related conditions.
- Vaccines: With an emphasis on public health, Sanofi supplies vaccines for poliomyelitis, pertussis, and Hib for children; influenza, adult boosters, meningitis, and vaccines for travel and endemic diseases for adults, highlighting its role in preventing infectious diseases across all age groups.
- Consumer Healthcare: Beyond prescription medicines, Sanofi extends its healthcare solutions to over-the-counter products. This includes allergy relief, cough and cold therapies, pain management, liver care, products promoting physical and mental wellness, probiotics, digestive health, and nutritional products. The range also features daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema, catering to a wide array of consumer health needs.
- Pharmaceutical Products and Vaccines in Development: Sanofi is actively involved in the development of new pharmaceuticals and vaccines, pointing to a future of continued innovation and enhanced healthcare solutions. This commitment to research and development ensures Sanofi remains at the forefront of addressing emerging health challenges.
